logo
Share SHARE
FONT-SIZE Plus   Neg

MEDA Says FDA Approved Dymista - Quick Facts

MEDA AB (MDABF.PK) said the U.S. Food and Drug Administration has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis, or SAR. In several clinical studies, Dymista has consistently showed a rapid and more complete symptom relief than standard treatment.

Anders Lönner, CEO of Meda AB, said, "...The approval of Dymista represents an important achievement for Meda's clinical development groups in the US and Europe. Meda's franchise in the allergy area is strengthened and gives opportunities for the company to grow and establish collaborations in the field. Dymista will be available in the US during the second half of 2012".

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations. Google is planning to significantly expand a carpool service on its navigational app Waze, according to a report in the Wall Street Journal. The move indicates the company is edging closer to a potential clash with ride-hailing service Uber Technologies Inc.
comments powered by Disqus
Follow RTT